Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2022


STOCKHOLM, July 5, 2022 /PRNewswire/ -- Zinzino group revenue increased with a total of 1% in Q2, compared with the previous year.

The revenue in June for Zinzino's sales markets increased by 2% and amounted to SEK 104.7 (102.8) million. Faun Pharma's external sales increased by 100% and amounted to SEK 8.0 (4.0) million. Overall, the Group increased revenues by 6% to SEK 112.7 (106.8) million compared with the previous year.

Sales in Zinzino's sales markets were unchanged in the second quarter of 2022 compared with the same period last year and amounted to SEK 306.1 (306.4) million. Total revenues in the Group increased by 1% in the second quarter and amounted to SEK 326.7 (322.4) million.

Accumulated revenue for January ? June 2022 increased by 1% compared with the same period last year and amounted to SEK 661.1 (655.8) million.

Revenues were distributed as follows:

Regions, mSEK

22-Jun

21-Jun

Change

Q2 2022

Q2 2021

Change

YTD 2022

YTD 2021

Change

The Nordics

24.3

32.3

-25 %

75.8

92.8

-18 %

156.1

186.6

-16 %

Central Europe

24.1

19.3

25 %

64.5

53.9

20 %

123.6

107.9

15 %

East Europe

24.3

23.7

3 %

76.6

79.4

-4 %

160.0

160.5

0 %

South & West Europe

12.9

12.6

2 %

36.5

37.0

-1 %

74.6

70.5

6 %

The Baltics

5.2

5.1

2 %

16.3

16.8

-3 %

34.6

35.6

-3 %

North America

7.5

4.2

79 %

18.1

10.5

72 %

32.2

25.1

28 %

Asia-Pacific

5.7

5.6

2 %

16.5

16.0

3 %

32.9

36.2

-9 %

Africa

0.7

0.0


1.8

0.0


3.2

0.0


Zinzino

104.7

102.8

2 %

306.1

306.4

0 %

617.2

622.4

-1 %

Faun Pharma

8.0

4.0

100 %

20.6

16.0

29 %

43.9

33.4

31 %

Zinzino Group

112.7

106.8

6 %

326.7

322.4

1 %

661.1

655.8

1 %

Countries in regions:

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 15:00 the 5th of July 2022.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-q2-2022,c3596926

The following files are available for download:

https://mb.cision.com/Main/10976/3596926/1601256.pdf

Pressrelease Salesreport Q2 2022


These press releases may also interest you

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...



News published on and distributed by: